Cost–utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan

Current Medical Research and Opinion

Volumn 33, Issue 1, 2017, Pages 1-10

  Igarashi, Ataru ^a   Tang, Wentao ^a   Cure, Sandrine ^b   Guerra, Ines ^b   Marié, Lucile ^b   Lopresti, Michael ^c   Tsutani, Kiichiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Mapi   (United Kingdom)

^c Junicon Japan Inc   (Japan)

Author keywords

Chronic hepatitis C infection; Cost utility analysis; Genotype 2; Japan; Sofosbuvir

Indexed keywords

PEGINTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT;

ARTICLE; CHRONIC HEPATITIS C; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; FEMALE; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; INCIDENCE; JAPAN; JAPANESE (PEOPLE); LIVER TRANSPLANTATION; MALE; MARKOV CHAIN; PHASE 3 CLINICAL TRIAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; TECHNOLOGY; TREATMENT DURATION; TREATMENT OUTCOME; COST BENEFIT ANALYSIS; ECONOMICS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; VIROLOGY;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; SOFOSBUVIR;

EID: 84986201358     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2016.1222512     Document Type: Article

References (33)

1. Sievert W, Altraif I, Razavi H, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver International 2011;31:61-80
2. Nakano T, et al. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver International 2012;32:339-45
3. Thein H-H, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection:a meta-analysis and meta-regression. Hepatology 2008;48:418-31
4. Kudo M, et al. Management of hepatocellular carcinoma in Japan:consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011;29:339-64
5. Sasaki Y, et al. Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma. Ann Surg 2006;244:771-80
6. Ikai I, et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res 2007;37:676-91
7. Tomoda T, et al. Genetic risk of hepatocellular carcinoma in patients with hepatitis C virus:a case control study. J Gastroenterol Hepatol 2012;27:797-804
8. Liu GG, et al. The burden of illness for patients with viral hepatitis C:evidence from a national survey in Japan. Value Health 2012;15(1 Suppl):S65-S71
9. Inoue Y, et al. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin:reducing drug doses has no impact on rapid and sustained virological responses. J Viral Hepat 2010;17:336-44
10. Kanda T, Imazeki F, Azemoto R, et al. Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2. Dig Dis Sci 2011;56:3335-42
11. Chung H, Ueda T, Kudo M., Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 2010;53:39-43
12. Tanaka J, Kumagai J, Katayama K, et al. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995–2000. Intervirology 2004;47:32-40
13. Asahina Y, et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 2010;52:518-27
14. Omata M, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection:an open-label, phase 3 trial. J Viral Hepatitis 2014;21:762-8
15. Shepherd J, et al. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C:a systematic review and economic evaluation. Health Technol Assess 2007;11:1-205, iii
16. Hartwell D, Jones J, Baxter L, Shepherd J. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection:a systematic review and economic evaluation. Health Technol Assess 2011;15:i-xii, 1-210
17. Fukuda TST, Ikeda S, Igarashi A, et al. [Guideline for economic evaluation of healthcare technologies in Japan]. J Natk Inst Publ Health 2013;62:625-640
18. Editors of the Drafting Committee for Hepatitis Management Guidelines:The Japan Society of Hepatology Guidelines for the management of hepatitis C virus infection. Hepatol Res 2013;43:1-34
19. Yamada I, Nakayasu Y., Telaprevir-based therapy for chronic hepatitis C in Japan:a summary of clinical study results. J Hepat Res 2015;2:1020
20. [JSH Guidelines for the Management of Hepatitis C Virus Infection]. 2015. Available at:https://www.jsh.or.jp/files/uploads/HCV_GL_ver4_Sept01_final.pdf. Last accessed 15 September 2015
21. EMA. Sovaldi, summary of product characteristics. Available at:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002798/WC500160597.pdf. Last accessed 16 September 2015
22. PegIntron, PMDA Review Report. Pharmaceutical and Medical Devices Agency Feron, PMDA review report. Pharmaceutical and Medical Devices Agency. Available at http://www.pmda.go.jp/drugs/2009/P200900047/48022000_22100AMX01812_A100_1.pdf. Last accessed 15 September 2015
23. Kumada H, et al. Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan. Hepatol Res 2015;45:745-54
24. Nakamura J, Terajima K, Aoyagi Y, Akazawa K. Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups. Tohoku J Experimental Med 2008;215:33-42
25. Ishida H, Yotsuyanagi H., [Study of the cost-effectiveness of the standard treatment for chronic hepatitis C]. Ministry of Health Labour and Welfare, 2013 Available at:https://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=201333004B. Last accessed 16 September 2015
26. The 21th Life Tables (2010). Ministry of Health, Labour and Welfare, 2010. Available at:http://www.mhlw.go.jp/english/database/db-hw/lifetb21th/dl/tables.pdf. Last accessed 15 September 2015
27. Sugimori H, Ikeda S, et al., [A study in the utility value of hepatitis]. Ministry of Health Labour and Welfare, 2013 Available at:https://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=201333004B. Last accessed 16 September 2015
28. Wright M, Grieve R, Roberts J, et al. Health benefits of antiviral therapy for mild chronic hepatitis C:randomised controlled trial and economic evaluation. Health Technol Assess 2006;10:1-113, iii
29. Telaprevir for the treatment of genotype 1 chronic hepatitis C–NICE technology appraisal guidance 252. National Institute for Health and Clinical Excellence, 2012. Available at:https://www.nice.org.uk/guidance/ta252
30. 2015 National Drug Tariff. Ministry of Health, Labour and Welfare, 2015 Available at http://www.mhlw.go.jp/topics/2014/03/tp0305-01.html. Last accessed 15 September 2015
31. Ikeda T., [Medical expenses for the viral liver diseases]. Ministry of Health Labour and Welfare, 2013 Available at:https://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=201333004B. Last accessed 16 September 2015
32. Shiroiwa T, Igarashi A, Fukuda T, Ikeda S. WTP for a QALY and health states:more money for severer health states? Cost Eff Resour Alloc 2013;11:22
33. Shiroiwa T, Sung Y, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained:what is the threshold of cost effectiveness? Health Economics 2010;19:422-37